


UNITED ARAB EMIRATES



Number of new cases

5 526

Number of deaths

2 283

Number of prevalent cases (5-year)

20 053


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	6 932 241	3 149 541	10 081 782
Incidence*			
Number of new cancer cases	2 607	2 919	5 526
Age-standardized incidence rate	86.4	157.8	105.1
Risk of developing cancer before the age of 75 years (cum. risk %)	9.6	16.9	11.6
Top 3 leading cancers (ranked by cases)**	Colorectum Prostate Bladder	Breast Thyroid Colorectum	Breast Colorectum Thyroid
Mortality*			
Number of cancer deaths	1 283	1 000	2 283
Age-standardized mortality rate	48.7	70.3	54.4
Risk of dying from cancer before the age of 75 years (cum. risk %)	4.9	7.5	5.6
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Leukaemia	Breast Colorectum Cervix uteri	Breast Colorectum Lung
Prevalence*			
5-year prevalent cases	8 542	11 511	20 053



Top 5 most frequent cancers**

Males




Total: 2 607

Rank	Cancer site	Number of cases	Percent
1st	Colorectum	346	13.3%
2nd	Prostate	310	11.9%
3rd	Bladder	190	7.3%
4th	Lung	184	7.1%
5th	Leukaemia	176	6.8%
-	Others	1 401	53.7%

Number of new cases in 2022, males, all ages

Females




Total: 2 919

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 142	39.1%
2nd	Thyroid	337	11.5%
3rd	Colorectum	204	7.0%
4th	Corpus uteri	152	5.2%
5th	Cervix uteri	138	4.7%
-	Others	946	32.4%

Number of new cases in 2022, females, all ages

Both sexes



Total: 5 526

Rank	Cancer site	Number of cases	Percent
1st	Breast	1 142	20.7%
2nd	Colorectum	550	10.0%
3rd	Thyroid	444	8.0%
4th	Prostate	310	5.6%
5th	Leukaemia	297	5.4%
-	Others	2 783	50.4%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	1 142	1	20.7	6.4	253	1	11.1	1.7	5 048	160.3
Colorectum	550	2	10.0	1.4	236	2	10.3	0.63	1 950	19.3
Thyroid	444	3	8.0	0.58	45	14	2.0	0.12	1 812	18.0
Prostate	310	4	5.6	1.6	62	12	2.7	0.20	1 320	19.0
Leukaemia	297	5	5.4	0.56	167	4	7.3	0.32	1 122	11.1
Lung	249	6	4.5	0.75	221	3	9.7	0.62	354	3.5
Bladder	229	7	4.1	0.70	70	10	3.1	0.21	872	8.7
NHL	211	8	3.8	0.48	76	9	3.3	0.20	822	8.2
Stomach	164	9	3.0	0.45	138	5	6.0	0.37	263	2.6
Corpus uteri	152	10	2.8	1.3	33	18	1.4	0.32	649	20.6
Cervix uteri	138	11	2.5	0.65	69	11	3.0	0.43	545	17.3
Brain CNS	133	12	2.4	0.23	114	6	5.0	0.26	599	5.9
Kidney	122	13	2.2	0.32	44	15	1.9	0.13	437	4.3
Ovary	105	14	1.9	0.62	61	13	2.7	0.48	390	12.4
Hodgkin lymphoma	95	15	1.7	0.14	19	22	0.83	0.06	398	4.0
Lip, oral cavity	94	16	1.7	0.21	39	16	1.7	0.08	332	3.3
Liver	89	17	1.6	0.28	86	7	3.8	0.26	122	1.2
Pancreas	85	18	1.5	0.26	79	8	3.5	0.25	90	0.89
Multiple myeloma	69	19	1.2	0.20	37	17	1.6	0.12	246	2.4
Larynx	54	20	0.98	0.16	27	20	1.2	0.09	199	2.0
Testis	42	21	0.76	0.05	3	28	0.13	0.00	186	2.7
Nasopharynx	36	22	0.65	0.09	23	21	1.0	0.07	134	1.3
Oesophagus	33	23	0.60	0.11	31	19	1.4	0.11	49	0.49
Melanoma	31	24	0.56	0.07	5	26	0.22	0.01	131	1.3
Gallbladder	19	25	0.34	0.06	14	23	0.61	0.05	31	0.31
Salivary glands	13	26	0.24	0.02	5	26	0.22	0.02	51	0.51
Oropharynx	12	27	0.22	0.02	7	25	0.31	0.01	44	0.44
Mesothelioma	10	28	0.18	0.03	10	24	0.44	0.03	14	0.14
Kaposi sarcoma	5	29	0.09	0.02	0	31	0.00	0.00	9	0.09
Vulva	3	30	0.05	0.01	0	31	0.00	0.00	12	0.38
Penis	3	30	0.05	0.01	1	29	0.04	0.00	11	0.16
Hypopharynx	2	32	0.04	0.00	1	29	0.04	0.00	5	0.05
All cancers	5 526	-	-	11.6	2 283	-	-	5.6	20 053	-
All cancers excl. NMSC	5 445	-	-	11.5	2 264	-	-	5.6	19 719	-

Data source and methods

Incidence



Country-specific data source: National cancer registry
Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

Mortality

Country-specific data source: No data
Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

